Heart Failure
We recommend
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.
ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and…
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…
Articles on this topic
Cardio-renal-metabolic syndrome in context
The increase in the incidence of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD),...
How Important is the Time Factor in the Treatment of Heart Failure?
Current guidelines emphasize the importance of early diagnosis and immediate treatment for…
The Latest Updates of ESC Recommendations for Heart Failure Treatment
What is new in heart failure therapy? At the annual congress of the European Society of…
Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their…
Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of…
Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Hypertension is among the most common etiological factors of heart failure with preserved…
Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
Empagliflozin entered the market as an antidiabetic drug operating on the principle of…
H₂FPEF Score for Estimating the Probability of Heart Failure with Preserved Ejection Fraction in Persons with Unexplained Dyspnea
The simple, validated H₂FPEF scoring system based on clinical and echocardiographic parameters,...
Diabetes mellitus and heart failure − interconnected units with complex pathogenesis
Diabetes mellitus (DM) represents a significant risk factor for the development of heart…
Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries
In developed countries, heart failure occurs in approximately 2% of the population, with an…
Subscribe
E-courses on this topic
Conferences news
Go to records
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
- Cardio-renal-metabolic syndrome in context
- The Latest Updates of ESC Recommendations for Heart Failure Treatment
- ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
Journal on this topic
Related topic